3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Mesothelioma
3
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Cholangiocarcinoma
1
Adenocarcinoma of Lung
1
Interventions
Cyclophosphamide
7
pembrolizumab
6
Radiotherapy
6
Cisplatin
6
Sunitinib
5
Carboplatin
5
Paclitaxel
4
Thymectomy
3
130-nm albumin-bound paclitaxel
3
selinexor
2
lenvatinib
2
fludarabine
2
Taxes
2
Robotic Surgical Procedures
2
Ramucirumab
2
Prednisone
2
Pemetrexed
2
Octreotide
2
Nivolumab
2
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide
2
Methylprednisolone
2
Imatinib Mesylate
2
Etoposide
2
Erlotinib Hydrochloride
2
Drug Therapy
2
Doxorubicin
2
Chemoradiotherapy
2
Celecoxib
2
zimberelimab
1
vorolanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thymoma
×
anetumab ravtansine
×
Thoracic
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled